Albion Financial Group UT reduced its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 1.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 128,698 shares of the financial services provider’s stock after selling 1,282 shares during the quarter. iShares Biotechnology ETF comprises about 1.2% of Albion Financial Group UT’s holdings, making the stock its 26th largest position. Albion Financial Group UT’s holdings in iShares Biotechnology ETF were worth $17,015,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Darwin Wealth Management LLC bought a new position in iShares Biotechnology ETF in the 3rd quarter valued at $29,000. Highline Wealth Partners LLC bought a new position in iShares Biotechnology ETF in the third quarter valued at about $30,000. Ashton Thomas Securities LLC bought a new stake in iShares Biotechnology ETF during the 3rd quarter worth about $36,000. Modus Advisors LLC acquired a new position in iShares Biotechnology ETF during the 4th quarter valued at about $41,000. Finally, Voisard Asset Management Group Inc. bought a new position in shares of iShares Biotechnology ETF in the 3rd quarter valued at about $59,000. Institutional investors and hedge funds own 62.45% of the company’s stock.
iShares Biotechnology ETF Price Performance
IBB opened at $136.10 on Wednesday. iShares Biotechnology ETF has a fifty-two week low of $123.60 and a fifty-two week high of $150.57. The firm has a 50 day simple moving average of $136.15 and a 200 day simple moving average of $141.84.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Read More
- Five stocks we like better than iShares Biotechnology ETF
- Business Services Stocks Investing
- Rivian: Weathering the Storm, Poised for Growth?
- 3 Warren Buffett Stocks to Buy Now
- Avient Stock: Manufacturing Play With Double-Digit Upside
- What to Know About Investing in Penny Stocks
- Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.